Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display - Cocktail

617 - Osimertinib in the Treatment of Leptomeningeal Disease in T790M-negative, EGFR-mutated NSCLC: A Case Report

Date

24 Nov 2018

Session

Poster display - Cocktail

Presenters

Lawrence Kasherman

Authors

L. Kasherman1, J. Chen2, H. Soudy1

Author affiliations

  • 1 Medical Oncology, St George Hospital, 2217 - Kogarah/AU
  • 2 Medical Oncology, St George Hospital, Kogarah/AU
More

Resources

Abstract 617

Case Summary

Leptomeningeal carcinomatosis (LMC) is a terminal event in advanced cancer, its incidence in epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) is increasing due to recent advances in systemic therapy and prolongation of survival.

Osimertinib is a third generation EGFR-tyrosine kinase inhibitor (TKI) with preclinical and early clinical studies showing activity against LMC resistant to previous TKI treatments and acquired T790M mutation.

We report a case of osimertinib in the treatment of LMC in a T790M-negative, EGFR-mutated NSCLC with significant clinical benefit and no toxicity.

Osimertinib is a potentially effective treatment for LMC associated with EGFR-mutated NSCLC regardless of T790M status and a well-tolerated treatment for poor performance status patients.

Editorial acknowledgement

Clinical trial identification

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings